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ABSTRACT
Metastasis is the predominant cause of death from cancer yet we have few 
biomarkers to predict patients at increased risk of metastasis and are unable to 
effectively treat disseminated disease. Analysis of 448 primary breast tumors 
determined that expression of the hylauronan receptor CD44 associated with 
high grade (p = 0.046), ER- (p = 0.001) and PR-negative tumors (p = 0.029), and 
correlated with increased distant recurrence and reduced disease-free survival in 
patients with lymph-node positive or large tumors. To determine its functional role 
in distant metastasis, CD44 was knocked-down in MDA-MB-231 cells using two 
independent shRNA sequences. Loss of CD44 attenuated tumor cell adhesion to 
endothelial cells and reduced cell invasion but did not affect proliferation in vitro. 
To verify the importance of CD44 to post-intravasation events, tumor formation was 
assessed by quantitative in vivo imaging and post-mortem tissue analysis following 
an intra-cardiac injection of transfected cells. CD44 knock-down increased survival 
and decreased overall tumor burden at multiple sites, including the skeleton in vivo. 
We conclude that elevated CD44 expression on tumour cells within the systemic 
circulation increases the efficiency of post-intravasation events and distant metastasis 
in vivo, consistent with its association with increased distant recurrence and reduced 
disease-free survival in patients.
INTRODUCTION
CD44 is a cell-surface trans-membrane protein and 
is the principal receptor for hyaluronic acid (HA), a major 
component of the ECM. Moreover, the CD44+/CD24−/low 
phenotype reputedly distinguishes tumorigenic from non-
tumourigenic breast cancer cells [1, 2]. CD44+/CD24−/low 
cells also exhibit enhanced invasive properties and favor 
distant metastasis [3, 4]. Furthermore CD44-expressing 
breast cancer cells with stem-like characteristics have been 
detected within the bone marrow of breast cancer patients 
presenting with early-stage disease [5].
As a result of differential splicing, CD44 is 
expressed as a series of standard (CD44s) or variant 
(CD44v) isoforms. Experimental studies in breast cancer 
models support that expression of standard and variant 
isoforms of CD44 increases disease-progressing and 
metastatic behavior. For example, tetracycline-regulated 
induction of CD44s in MCF-7 cells in vivo increases their 
dissemination of breast cancer cells to the liver [6] while 
CD44 enrichment has been detected in estrogen receptor 
(ER)-negative breast cancer cells that have disseminated to 
regional lymph nodes [7]. Furthermore, isoform-switching 
to promote expression of CD44s has been reported as 
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being critical to epithelial-mesenchymal transition (EMT) 
in breast cancer models in vivo, promoted through the 
activation of Akt signalling [8]. However, there is a marked 
discordance between experimental and clinical data in 
the literature. For example, recent immunohistochemical 
studies report that CD44s expression correlates with 
improved overall survival in breast cancer patients, and 
specifically to increased survival in patients with lymph 
node involvement [9]. Earlier studies measuring mRNA 
and protein levels also report CD44s to be predictive 
of better outcome. As such, there is a continued need 
to develop a comprehensive understanding of the 
biochemistry, pharmacology and functional roles of CD44, 
in order to articulate the significance of this glycoprotein 
in disease.
Increased stromal HA production is also associated 
with poorly differentiated and infiltrating breast 
carcinomas, the spread of tumor cells to axillary lymph 
nodes and decreased survival [11, 12]. HA and CD44 
co-localize in disseminated lesions within the lymph 
nodes, supporting a role for this receptor in mediating the 
HA-induced regional spread of breast cancer, consistent 
with recent immunohistochemical studies. With respect 
to potential roles in metastasis, HA is detected in the 
bone marrow sinusoidal endothelium and the lung 
microvasculature [13–15], two prominent sites of breast 
cancer metastasis. HA presentation on the endothelium 
is proposed to assist the homing of CD44-positive 
haematopoietic progenitor cells. Furthermore, high levels 
of circulating HA have recently been reported to inhibit 
metastasis, through a mechanism attributed to its role in 
preventing tumor cell interactions with the HA-displayed 
on the vascular endothelial cells [16].
Outgrowth of secondary tumors is initially 
dependent on the adhesion of circulating tumor cells to 
the endothelium lining the blood vessels within those 
tissues and their subsequent transmigration across 
the endothelial barrier. It is proposed that tumor cells 
adopt similar strategies as exploited by lymphocytes 
in undergoing extravasation [17, 18]. CD44 has a well-
described role in mediating the adhesion and extravasation 
of T-lymphocytes in in vitro and in vivo models, initiating 
and underpinning a subsequent integrin receptor-promoted 
“firm” adhesion [19–22]. Similarly, we have previously 
shown that CD44 potentiates the adhesion of breast and 
prostate cancer cells to bone marrow endothelial cells 
(BMECs) in vitro [23, 24], suggesting that CD44 may 
contribute to the efficiency of distant metastasis through 
its capacity to function as an adhesion receptor, facilitating 
the escape of cells from the circulation. Given our prior 
demonstration that elevated CD44 expression may initiate 
adhesion of cells to distant endothelial monolayers 
[23, 24], the objective of this study was to characterize 
the importance of CD44 in regulating post-intravasation 
events and distant metastasis of breast cancer in vivo.
RESULTS
CD44 expression predicts reduced disease free 
survival and distant recurrence in breast cancer 
patients
The clinical significance of CD44 was evaluated 
by immunohistochemical analysis of a breast cancer 
tissue microarray constructed using primary tissue from 
448 patients. CD44 was predominantly expressed on 
the plasma membrane of breast tumor epithelial cells 
(Fig. 1A). Based on the proportion of positive tumor 
cells and the intensity of the staining, 62% of cases were 
considered strongly positive for CD44 (Table 1). Strong 
CD44 expression associated with high-grade tumors 
(0 = 0.046), progesterone receptor negative (p = 0.029) 
and estrogen receptor α-negative tumors ( p = 0.001) 
(Table 1). There was no association of CD44 with nodal 
status, age or HER2 expression (Table 1).
Kaplan-Meier analysis confirmed that high 
CD44 expression predicted for reduced disease-free 
survival in lymph node-positive patients ( p = 0.019) 
(Fig. 1B) and patients with large tumor size (> 2.5 cm) 
( p = 0.012) (Fig. 1C). CD44 correlated with clinically/
pathologically-confirmed distant recurrence in the 
entire cohort ( p = 0.046) (see Supplemental Figure S1); 
moreover, the significance value further increased when 
distant recurrence was considered only in the context of 
lymph-node positive tumors ( p = 0.011; Fig. 1D) and large 
tumors ( p = 0.004; Fig. 1E).
CD44 expression is associated with metastasis-
related phenotypes
To ascertain the functional importance of CD44 in 
the context of estrogen receptor negative breast cancers, 
we used the CD44-expressing MDA-MB-231 cell line, 
which retains the CD44+/CD24−/low phenotype characteristic 
of tumor-initiating breast cancer cells. To assist in vivo 
experimentation, we exploited two independent shRNA 
sequences to repress CD44 expression in luciferase-labeled, 
MDA-MB-231-Luc-D3H2LN cells. Cells transfected 
with sh#1 exhibited negligible CD44 expression while 
transfection with sh#2 resulted in an intermediate level of 
CD44 repression relative to parental cells and transfection 
with a non-targeting sequence (shNT) (Fig. 2A). To 
determine the functional role of CD44 expression we 
performed a series of in vitro assays using parental, shNT-, 
sh#1- and sh#2-transfected cells. CD44 depletion did not 
affect cell proliferation (Fig. 2B), nor cause detachment 
of cells or induce anoikis. However, sh#1- and sh#2-
transfected cells were significantly less invasive through 
Matrigel™ than the parental or shNT-transfected cells 
(each p < 0.05; Fig. 2C) and showed reduced adhesion to 
a monolayer of bone marrow endothelial cells (BMECs) 
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Figure 1: CD44 expression predicts for reduced disease-free survival and increased distant recurrence in breast cancer 
patients. A. Representative images of CD44 immunoreactivity determined by an immuno-histochemical study of tissue microarray 
sections from a cohort of 448 breast cancer patients. Images shown represent low and high CD44 staining at a magnification of x100. 
B. Kaplan Meier survival curves stratifying disease-free survival according to CD44 expression in node-positive patients and C. patients 
with large tumor size (> 2.5 cm). D. Kaplan Meier estimates of distant metastasis-free survival in node positive patients and E. patients 
with large tumor size (> 2.5 cm) (where recurrence is defined by distant recurrence only).
( p < 0.05; Fig. 2D). These functional assays confirm an 
important role for CD44 in regulating cell adhesion and 
invasion but not proliferation.
CD44 expression correlates with increased 
metastasis and decreased survival to ethically 
mandated euthanasia in mice
To directly test whether CD44 is required for the 
post-intravasation stages of the metastatic cascade, 
tumor formation was assessed following the intra-cardiac 
injection of shNT-, sh#1-, sh#2-transfected MDA-MB-
231-Luc-D3H2LN cells in athymic nude mice. By 
injecting cells directly into the circulation, this approach 
eliminates the effects that CD44 may have during the early 
stages of metastasis and permits an exclusive study of the 
relevance of CD44 to post-intravasation events. Systemic 
dissemination and tumor growth profiles of the inoculated 
cells were monitored in vivo using bioluminescent 
imaging, and confirmed by post-mortem histology.
Oncotarget11468www.impactjournals.com/oncotarget
CD44 knock-down in the injected MDA-MB-231-
Luc-D3H2LN cells significantly extended the survival 
to ethically mandated euthanasia of recipient mice, with 
the maximum repression of CD44 (using sh#1) increasing 
median survival from 34 to 52 days ( p = 0.027) (Fig.  3A). 
Overall tumor burden was reduced following injection 
with sh#1- and sh#2-transfected cells relative to control 
shNT-transfected cells (Fig. 3B). Sh#1 was significantly 
different from shNT at weeks 3, 4 and 5 post-tumor cell 
injection. While sh#2 although showing the same trend 
as sh#1 was significantly different from shNT at week 5 
only (**p < 0.01, *p < 0.05). Tumors arising following 
the injection of shNT-transfected MDA-MB-231 cells 
were detectable in brain, liver, heart, lungs and bones 
(Fig. 3C). Comparison on the same bioluminescence 
scale clearly illustrates the more efficient development 
of multiple tumors following injection of CD44 positive 
cells (shNT) compared to animals injected with CD44 
depleted (sh#1 and sh#2) cells. Although tumors are also 
present in the animals injected with CD44-depleted cells 
the luminescent light emission is below the minimum of 
the displayed scale in this Fig. 3C. Tumor burden as 
indicated by bioluminescent imaging was subsequently 
confirmed by histology. Representative image of CD44 
positive brain metastasis arising following injection of 
shNT cells is shown in Fig. 3D. Notably although CD44 
knockdown varies between the two shRNA constructs, 
there is no significant difference in the tumourigenicity of 
cells transfected with CD44 sh#1 and sh#2 suggesting that 
even an incomplete reduction of CD44 is associated with 
a less aggressive phenotype.
CD44 expression promotes bone metastasis
A high level of metastasis to the hind limbs was 
clearly evident. Subsequent analysis of hind limbs 
revealed a reduced tumor burden 4-weeks post-injection in 
CD44-depleted conditions, with a 1132-fold lower signal 
detected in the sh#1-transfected model (n = 6, p = 0.033) 
and 1137-fold decrease observed in the sh#2-transfected 
model (n = 6, p = 0.047) relative to the shNT control 
(Fig. 4A). X-ray analysis confirmed the presence of 
osteolytic lesions in the tibia of mice injected with the 
shNT-transfected MDA-MB-231 cells. In contrast, bone 
resorption was not apparent in the hind limbs of mice 
injected with either of the CD44-depleted MDA-MB-231 
cells (Fig. 4B). The presence of bone metastasis was 
confirmed by histology. H&E stained de-mineralized 
bone sections revealed a decreased tumor burden in the 
bones of animals injected with sh#1- or sh#2-transfected 
MDA-MB-231 cells (Fig. 4C). Immunohistochemistry 
confirmed that bone metastases arising from injection 
Table 1: Table showing the association of CD44 expression with clinical pathological parameters in 
a breast cancer patient cohort
Association of CD44 expression with clinical pathological parameters using Fishers exact test
% CD44 % P
CD44 + 62.5
− 37.5
Grade I-II 54.3 55.3
III 45.7 65.0 0.046
Node + 51.8 61.5
− 48.2 63.6 0.693
Age > 55 51.5 63.8
< 55 48.5 61.1 0.56
ER + 67.9 57.3
− 32.1 73.2 0.001
PR + 51.5 66.4
− 48.5 71.2 0.029
Her2 + 19.5 55.2
− 80.5 61.9 0.715
NOTE: Expression of CD44 is expressed as a % of patients in individual clinical classifications (1st column)
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of shNT-transfected MDA-MB-231 cells were strongly 
positive for CD44 (Fig. 4D).
Bone-tropic breast cancer cells have elevated 
CD44 expression and demonstrate increased 
adhesion properties
Although metastasis of shNT-transfected MDA-
MB-231 cells to bone was not an exclusive event, 
our in vivo study supported a role for CD44 in the 
efficient outgrowth of metastatic bone lesions. The 
importance of CD44 in supporting the dissemination of 
breast cancer cells to the bone was further investigated 
in vitro. Consistent with our in vivo results bone-tropic 
MDA-MB-231 cells (MDA-MB-231BO) expressed 
higher levels of the standard form of CD44 (CD44s) than 
the parental cell line (Fig. 5A). Moreover, these bone-
tropic MDA-MB-231BO cells were significantly more 
adherent to BMECs than parental cells at all time points, 
(*p < 0.05) (Fig. 5B).
Figure 2: Knock-down of CD44 has no effect on cell proliferation but reduces adhesion and cell invasion. A. Western 
blot showing CD44s expression in parental (Par) MDA-MB-231 cells and following transfection of these cells with either CD44 sh#1, 
CD44 sh#2 or non-targeting (shNT) control shRNA constructs. B. Curve confirming the absence of an effect of CD44 knock-down on 
cell proliferation rates, measured using MTT assays performed over 96 hours. C. Bar graph presenting data obtained from modified 
Boyden chamber assays measuring cell invasion of the indicated clones through Matrigel®. D. Bar graph presenting adhesion assay 
data demonstrating the effect of CD44 knock-down upon the efficiency of adhesion over 30 min of the clonal MDA-MB-231 cells to 
a monolayer of bone marrow endothelial cells (BMECs). All data shown are mean ± SEM of at least 3 independent experiments (*p < 0.05 
by t-test)
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Figure 3: Knock-down of CD44 improves survival to ethically mandated euthanasia and decreases metastasis 
in vivo. A. Kaplan-Meier survival curve of mice inoculated with MDA-MB-231 shNT (n = 5), CD44 sh#1 (n = 5) or sh#2 (n = 3) cells 
(comparison of shNT and sh#1 p = 0.0269 by Log Rank test). B. Normalized quantification of bioluminescent signals determined at weekly 
intervals in mice from shNT (n = 7), sh#1 (n = 8) and sh#2 (n = 7) groups. Sh#1 was significantly different from shNT at weeks 3, 4 and 5 
post-tumor cell injection, while sh#2 was significantly different from shNT at week 5 only. Data represent the mean ± SEM (**p < 0.01, 
*p < 0.05 by t-test). C. Representative images of mice from each group taken 35 days post-intra-cardiac injection of MDA-MB-231 
clones; multiple metastases are detected in CD44+ve shNT cohort compared to CD44-depleted sh#1 and sh#2 cohorts. Pseudocolour 
scale bar is consistent for all images. D. Representative H&E stain of a brain section from a mouse inoculated with MDA-MB-231 shNT 
cells and corresponding tumor-specific CD44 immunohistochemistry. Magnification is x40 for H&E image, x40 for left image of CD44 
immunoreactivity and x200 for right image of CD44 staining. T = Tumor, Br = Brain.
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Figure 4: CD44 expression promotes bone metastasis. A. Normalised quantification of bioluminescent signals from mice hind 
limbs injected with indicated clones. Data represents the mean ± SEM (n = 6; *p < 0.05 by t-test). B. Representative digital radiographs 
of hindlimbs from mice in each experimental group. White arrows indicate osteolytic bone lesions. C. Representative demineralized bone 
sections from each experimental group. H&E-stained sections showing complete replacement of bone marrow by tumor in shNT-mice 
(left) compared with absence of tumor cells in mice injected with sh#1 and sh#2 clones (middle and left). All images are x50 magnification 
with scale bar equal to 100 μm. D. Representative tumor-specific CD44 immunoreactivity (note strong membraneous staining) and 
corresponding H&E stain of demineralized bone sections from mice inoculated with MDA-MB-231 shNT cells. Magnification is x50 
for H&E image (left) and left image of CD44 immunoreactivity and x200 for right image of CD44 staining; scale bar equal to 100 mm. 
T = tumor BM = bone marrow.
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Figure 5: Bone metastatic MDA-MB-231 cells express high levels of CD44. A. Western blot comparing the expression of 
CD44s between parental (Par) and bone-tropic (BO) MDA-MB-231 cells. Blots shown are representative of 3 independent experiments. 
B. Comparison of the rate of parental (Par) and bone-tropic (BO) MDA-MB-231 cell adhesion to BMECs over 30 min. All data is the 
mean ± S.E.M of three at least three independent experiments (*p < 0.05; by t-test).
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DISCUSSION
Contrary to the findings of several previous 
immunohistochemistry studies, our analysis of an 
extensive breast cancer tissue cohort of 448 patients 
reveals CD44 expression to correlate with reduced 
disease-free survival and distant metastasis in lymph 
node-positive patients and patients with large tumor 
size. In trying to reconcile the obvious differences with 
published findings, the antibody used in our tissue study 
detects both standard and variant isoforms of CD44, and 
therefore, may explain the contrasting results which have 
correlated CD44s expression, detected by a monoclonal 
antibody, with favorable overall survival, albeit in a 
significantly smaller tumor cohort (51 patients) [9]. 
Furthermore, it is possible that a high CD44v/CD44s ratio 
in our tumor cohort may also bias the results of our study 
in favor of poor clinical outcome, consistent with the 
correlation of CD44v6 with TNM stage [10]. However, 
it is important to stress that this current analysis has 
reaffirmed our correlation of CD44 to ER- and PR-null 
tumors, linking high CD44 expression to basal-like breast 
cancer, a subtype of this disease known to have the worst 
prognosis and most aggressive form of disease. As such, 
the association of CD44 to reduced disease-free survival 
and distant metastasis in lymph node-positive tumors may 
not be surprising. Importantly, correlations of CD44s or 
CD44v expression against these well-established and 
validated markers in breast cancer were not reported in 
prior immunohistochemical studies.
Without dispute is evidence in breast cancer that 
CD44 is expressed by primary tumors, in regional lymph 
node metastases, and early disseminated “stem-like” 
tumor cells within the bone marrow of patients [5, 12]. 
Experimentally, induction of CD44 increases the incidence 
of MCF-7 cell metastasis to the liver [7]. However, these 
studies cannot discriminate between the role of CD44 in 
promoting the initial escape of tumor cells at the primary 
site from the role it may play in promoting colonization 
and outgrowth of secondary lesions at distant sites. In 
focusing on the later stages of the metastatic cascade, 
our study definitively shows that CD44 contributes 
to post-intravasation events of the metastatic cascade 
in vivo, where CD44 expression correlates with increased 
tumor burden at distant sites and reduces survival. This 
experimental observation reaffirms our correlation of 
CD44-positivity in primary breast cancer tissue with 
reduced disease-free survival in patients with confirmed 
distant metastasis. Integrating this experimental and 
clinical data therefore provides important and novel 
insights into the role and importance of CD44 in enhancing 
the efficiency of later stages of tumor dissemination.
We observed tumor development in multiple tissues 
and organs following intra-cardiac injection of CD44-
expressing MDA-MB-231 cells. Down-regulation of 
CD44 decreased the rate of onset and the magnitude of 
tumor burden in the animals, at all clinically-relevant sites 
including the brain, lung, liver and skeleton, indicating 
that CD44 does not preferentially select for the metastasis 
of breast cancer cells to specific tissues. Furthermore, 
loss of CD44 correlated with an increased survival of 
the mice. In tissue, CD44 was not statistically associated 
with disease-free survival across the entire cohort but was 
significant to disease-free survival and distant metastasis 
when assessed in the context of lymph-node positive 
tumors and/or large tumors. Therefore, our studies support 
that elevated CD44 expression can predict an increased 
risk of distant metastasis and reduced disease-free survival 
in discrete sub-populations of breast cancer patients.
In vivo modeling confirmed that injection of 
CD44-expressing cells resulted in the formation of 
metastatic lesions at multiple, clinically-relevant sites. 
Bone metastasis is particularly common in breast cancer 
[25] while the bone marrow may serve as an important 
site for dormant breast tumor cells [26]. Interestingly, 
CD44 positive, “stem-like” breast cancer cells have been 
detected within the bone marrow during early stage disease 
[3, 5]. Although our data indicates that CD44 does not 
preferentially select for tissue-specific metastasis in vivo, 
CD44 knockdown on stem-cell-like CD44+/CD24−/low  
MDA-MB-231 cells did significantly decrease tumor 
burden and reduced the incidence of metastatic lesions 
in the hind limbs of animals. The importance of CD44 
in promoting the colonization of bone by breast tumor 
cells is further supported by our in vitro experiments. 
For example, we show that bone-tropic MDA-MB-231 
cells show elevated expression of CD44 relative to their 
parental line in vitro, and consistent with our previous 
characterization of the importance of CD44 in initiating 
cell-cell adhesion [23, 24], these bone tropic cells were 
more efficient in adhering to BMECs. Thus, elevated 
CD44 expression on tumourigenic cells may increase the 
efficiency with which circulating cells can acquire entry to 
and colonize the bone.
The knockdown of CD44 on MDA-MB-231 cells 
also decreased their invasion through an experimental 
matrix. In a further recent study, we have shown that the 
activation of CD44 results in an increased transcription 
and synthesis of key proteases of the serine proteinase, 
cysteine cathepsin and matrix metalloproteinase families 
[27]. In particular, the capacity of CD44 to increase 
cathepsin K and MT1-MMP is especially relevant given 
that these two enzymes are extremely potent in degrading 
collagen I, and therefore initiate the degradation of the 
collagen-enriched bone matrix. Therefore, in the context 
of bone metastasis alone, we propose that the increased 
level of osteolytic lesions detected in the hind limbs of 
mice injected with CD44-expressing MDA-MB-231 cells 
may relate to the capacity of CD44 to not only increase 
uptake of circulating tumorigenic cells, but also to assist 
the capacity of these infiltrating cells to initiate turnover 
of the bone and colonization.
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In conclusion, our study confirms that the 
expression of CD44 increases the efficiency with which 
tumourigenic breast cancer cells can successfully 
complete the distant steps of the metastatic cascade. 
Studies conducted on human tissue and through 
in vivo modeling confirm that CD44 expression 
correlates with distant metastasis and reduced survival. 
These observations are consistent with our prior 
characterization of CD44 in initiating the arrest and 
adhesion of breast cancer cells on vascular endothelial 
cells [23, 24] and in upregulating the expression of 
proteases associated with the degradation of key matrix 
proteins in clinically-relevant tissues [27]. Overall, 
our data implies that CD44 can promote tumor cell 
adhesion to endothelial barriers and facilitating localized 
invasion/colonization within the tissue, rather than 
promoting or increasing the rate of cell proliferation at 
secondary sites. Interestingly, our results take on added 
clinical significance when one considers that this study 
and other recent reports indicate that CD44 expression 
is especially enriched in ER-negative, PR-negative and/
or Her2-negative breast cancers which have the worst 
clinical prognosis and outcome [28].
MATERIALS AND METHODS
Antibodies and reagents
Anti-CD44 was obtained from R&D systems, UK. 
HRP-conjugated secondary antibodies were obtained from 
Amersham, UK and Hyaluronan (MW220 kDa) from 
Lifecore Biomedical (MN, USA). Cells were stimulated 
with 100 μg/ml HA for indicated times. All other reagents 
were purchased from Sigma (Poole, UK) unless otherwise 
stated.
Cell culture
Luciferase-expressing MDA-MB-231 cells 
(MDA-MB-231-Luc-D3H2LN) were purchased from 
Caliper Life Sciences (Cheshire, UK). SureSilencing™ 
CD44-shRNA#1, CD44-shRNA#2 or non-targeting-
shRNA constructs (Superarray Bioscience, MD, 
USA) were transfected using Lipofectamine2000, 
(Invitrogen, UK).
Puromycin-resistant clones were screened for 
CD44-knockdown by Western-blotting. A bone-tropic 
clone of the MDA-MB-231 cell line (MDA-MB-231BO) 
was provided by Prof. Yoneda, University of Osaka [29]. 
Cells were maintained in DMEM supplemented with 
10%(v/v) FCS (PAA). Human bone marrow endothelial 
cells (BMECs) obtained from Dr. Weksler (Weill College 
of Medicine, Cornell University, NY) were maintained in 
DMEM supplemented with 5%(v/v) FCS, 10 mM HEPES 
and 3 mM L-glutamine.
Breast cancer xenograft and bioluminescence 
analysis
Female athymic nu/nu mice aged 6–8 weeks 
(Harlan) were anesthetized by inhalation of 2–3% 
Isofluorane before injecting 1 × 105 sh#1, sh#2 or shNT 
transfected MDA-MB-231-Luc-D3H2LN cells into the left 
cardiac ventricle. Bioluminescent imaging was achieved 
by intraperitoneal injection of D-luciferin (150 mg/kg). 
Successful intracardiac injection was indicated by 
systemic bioluminescence throughout the animal; only 
mice with evidence of successful injection were included 
in the study. Development of metastasis was assessed by 
weekly imaging. Metastasis was quantified by selecting 
a region of interest and measuring the total photon flux 
(p/s) using Living Image® software v3.2 (Caliper Life 
Sciences, Cheshire, UK). Background bioluminescence 
was subtracted from the totals. Animals were weighed 
twice per week and were euthanized when they lost 20% 
of their starting weight or when they exhibited first signs 
of morbidity or paralysis. If any animal developed tumors 
at sites that would compromise feeding or excretion, 
they were removed from the study and euthanized by 
an approved schedule 1 means as stipulated by the 
Home Office.
Bone histology
Bones were collected upon euthanasia, fixed in 
10% formalin for 24 h, demineralised in 5% EDTA 
containing 1% formalin for 2 weeks, then processed 
using standard histological techniques. Demineralised 
bone sections were stained with Haematoxylin and Eosin 
or with anti-CD44 (1:400, detection using Envision™ 
detection kit, Dako).
Invasion and adhesion assay
Cell invasion and adhesion were assayed as 
described [23, 24] except tumor cells were harvested by 
scraping for adhesion assays.
Patients
Breast tumor samples were collected from archival 
cases at St Vincent’s University Hospital, Dublin, Ireland 
as previously described [30]. As detailed in table 1 45.7% 
of cases were high grade tumours, 51.8% of individuals 
were lymph node positive, 51.5% of individuals were 
greater than 55 years of age, 60.4% of tumours were 
greater than 2.5 cm in size, 67.9% were estrogen receptor 
positive, 51.5% were progesterone receptor positive and 
19.5% were Her2 positive. 40.3% of patients received 
chemotherapy, 60.9% received radiotherapy and 70.1% 
received tamoxifen.
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Tissue microarray construction and 
immunohistochemistry
Four μm sections were cut from the TMA and 
immunostained with anti-CD44 (1:200) on an automated 
platform (Bond™ system - Vision BioSystems™, 
Mount Waverley, Victoria, Australia). Sections were 
counterstained with hematoxylin. Negative controls were 
included by omission of primary antibody. Positive control 
tissue (normal thymus) was also used. Immunostained 
slides were scored on the proportion of positive tumor 
cells (range 0–5) and average staining intensity of positive 
cells (range 0–3) which were added together to obtain 
a total score (range 0–8) as described [31]. Cases were 
classified as negative (0–2), low (3–5) or high expression 
(6–8). All cores were examined by two independent 
observers (SMcF and PT) and 10% were also scored by a 
third independent observer (EK).
SDS-PAGE and western-blotting
Cell lysates (20 μg) were separated by SDS-PAGE 
and transferred onto immobilon-P PVDF membranes 
(Millipore, Billerica, MA, USA). Membranes were 
blocked for 1 h at RT in Tris-buffered saline/0.1% 
Tween-20 (TBS-T) containing 5%(v/v) dried milk. 
Incubation with primary antibody was carried out at 4°C 
overnight. Membranes were washed three times in TBS-T 
and then incubated for 1 h with the appropriate horse-
radish peroxidase (HRP)-labeled secondary antibody. 
Following three washes in TBS-T, immunoreactivity was 
detected using SuperSignal West Pico Chemiluminescent 
Substrate (Pierce Biotechnology, Rockford, IL, USA) 
followed by exposure to X-ray film.
Statistical analysis
Univariate analysis of tissue-derived data was 
performed using Fisher’s exact test for categorical values 
and Wilcoxon’s test for continuous variables. Multivariate 
analysis was conducted using Cox’s proportional hazard 
model. A two-tailed P value < 0.05 was considered 
significant. Kaplan-Meier survival analysis was generated 
and Wilcoxon tests employed to determine significance. For 
analysis of functional in vitro assays and in vivo experiments, 
significance was assessed using Student’s t-test, two tailed 
for functional assays and one tailed for analysis of in vivo 
experiments. A p-value < 0.05 was considered significant.
Ethical approvals
Animal studies were approved by the Biological 
Resource Unit Review Board at QUB and conducted 
under a Home Office Licence in compliance with UK 
legislation. Written and informed consent was received 
from all patients prior to the inclusion of tissue specimens 
in the TMA on which this study was conducted.
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